U.S. Markets open in 1 hr 44 mins

GBT Reports Third Quarter And 9M18 Results

DOUBLE-DIGIT EBITDA GROWTH AND FOCUS ON LAUNCHES AND EXECUTION

COMPANY ALIGNMENT ON LONG-TERM STRATEGIC AGENDA AND INVESTMENT ON OPERATION

MONTEVIDEO, Uruguay, Nov. 12, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3:GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 3Q18 and 9M18.

HIGHLIGHTS

Net revenues for 3Q18 increased by 2% in constant currency, also impacted by discontinued business and SOLVADI®, marking BRL 829M LTM (including hyperinflation adjustment). 

Gross profit rose by 16% vs. 3Q17, in constant currency.

Gross margin of 51% (including hyperinflation adjustments) vs. 50% in 3Q17.

Adjusted EBITDA grew by 34% in constant currency vs. 3Q17.

Adjusted EBITDA margin came to 24% in 3Q18 (including hyperinflation adjustment), improving 283 bps vs. 3Q17.

Net income totaled BRL 13M in 3Q18 (including hyperinflation adjustment) from a loss of BRL 8M in 3Q17.

Adjusted net income up 82% from 3Q17, in constant currency.

Launches of new products continue to be main focus.

Contacts:
Melissa Angelini
ir@grupobiotoscana.com 
+55 11 5090-5927 

Cision

View original content:http://www.prnewswire.com/news-releases/gbt-reports-third-quarter-and-9m18-results-300748842.html